Main Article Content
In the previous study, the colonic release of ibuprofen pellet has been developed by using the microbial dependent release system which was successfully obtained by using the dual coatings. Pharmacokinetic study of this pellet had been done in New Zealand albino rabbit and showed delay absorption, but better bioavailability compared to conventional oral preparation. Therefore, the aim of this study is to explore the potential benefit of this formulation in minimizing the main side effect of ibuprofen: gastric duodenal ulcer. To study the suppression effect on ulcer in vivo, male Wistar rats were used and divided into 4 groups: negative control, group given ibuprofen suspension, group given uncoated ibuprofen pellet and group with coated ibuprofen pellet. All treated groups were administered orally twice a day for 14 days. Then, parameters including platelet counts and observation on gastroduodenal ulcer development both visual and histological analyses were performed. Groups receiving both suspension and uncoated pellet of ibuprofen showed ulcer development, meanwhile this condition did not occur in rats treated with coated pellet. Colonic release of ibuprofen seems to be promising in the suppression of ulceration. The efficacy of anti-inflammatory activity of the formula is now under progress.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.